22MA043N ACT: Targeting Myeloid-Derived Suppressor Cells (MDSCs) In Bladder Cancer to Enhance Efficacy of Adoptive Cell Therapy (ACT)
FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CONTACT OUR OFFICE
The Innovation Office
InnovationMarketing@Moffitt.org
(813) 745-6828